Zimmer Biomet Holdings, Inc.
General ticker "ZBH" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $20.0B (TTM average)
Zimmer Biomet Holdings, Inc. does not follow the US Stock Market performance with the rate: -11.4%.
Estimated limits based on current volatility of 1.5%: low 92.71$, high 95.47$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2025-12-30, amount 0.24$ (Y1.02%)
- Total employees count: 17000 (-5.6%) as of 2024
- US accounted for 57.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market competition, Supply chain disruptions, Cybersecurity threats, Regulatory and compliance, ERP system transition
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [75.14$, 112.47$]
- 2026-12-31 to 2027-12-31 estimated range: [77.13$, 115.16$]
Financial Metrics affecting the ZBH estimates:
- Negative: with PPE of 11.0 at the end of fiscal year the price was high
- Positive: 7.67 < Operating profit margin, % of 16.55
- Positive: 6.64 < Operating cash flow per share per price, % of 9.50
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 2.96
- Positive: -14.22 < Investing cash flow per share per price, % of -11.06
- Positive: Inventory ratio change, % of -0.81 <= -0.75
- Positive: Interest expense per share per price, % of 1.64 <= 3.28
- Positive: 42.68 < Shareholder equity ratio, % of 55.02 <= 64.29
- Negative: Industry inventory ratio change (median), % of 0.58 > 0.31
Short-term ZBH quotes
Relationship graph
Long-term ZBH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $7,394.20MM | $7,678.60MM | $8,231.50MM |
| Operating Expenses | $6,116.50MM | $6,392.90MM | $6,869.30MM |
| Operating Income | $1,277.70MM | $1,285.70MM | $1,362.20MM |
| Non-Operating Income | $-210.40MM | $-249.10MM | $-531.40MM |
| Interest Expense | $201.20MM | $218.00MM | $292.80MM |
| R&D Expense | $458.70MM | $437.40MM | $458.50MM |
| Income(Loss) | $1,067.30MM | $1,036.60MM | $830.80MM |
| Taxes | $42.20MM | $131.40MM | $125.70MM |
| Profit(Loss)* | $1,024.00MM | $903.80MM | $705.20MM |
| Stockholders Equity | $12,480.50MM | $12,468.10MM | $12,705.80MM |
| Inventory | $2,385.20MM | $2,235.30MM | $2,286.40MM |
| Assets | $21,496.90MM | $21,365.30MM | $23,091.70MM |
| Operating Cash Flow | $1,581.60MM | $1,499.40MM | $1,697.00MM |
| Capital expenditure | $394.50MM | $356.80MM | $224.50MM |
| Investing Cash Flow | $-778.90MM | $-888.10MM | $-1,975.70MM |
| Financing Cash Flow | $-763.50MM | $-484.50MM | $326.00MM |
| Earnings Per Share** | $4.91 | $4.45 | $3.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.